Similar articles

• Inhibition of type-5 phosphodiesterase: promising therapy for pulmonary hypertension.

  Watanabe H. Watanabe H. Intern Med. 2004 Oct;43(10):891-3. doi: 10.2169/internalmedicine.43.891. Intern Med. 2004. PMID: 15575233 No abstract available.
• KF31327, a new potent and selective inhibitor of cyclic nucleotide phosphodiesterase 5.

  Hirose R, Okumura H, Yoshimatsu A, Irie J, Onoda Y, Nomoto Y, Takai H, Ohno T, Ichimura M. Hirose R, et al. Eur J Pharmacol. 2001 Nov 9;431(1):17-24. doi: 10.1016/s0014-2999(01)01422-4. Eur J Pharmacol. 2001. PMID: 11716838
• Cyclic GMP phosphodiesterase-5: target of sildenafil.

  Corbin JD, Francis SH. Corbin JD, et al. J Biol Chem. 1999 May 14;274(20):13729-32. doi: 10.1074/jbc.274.20.13729. J Biol Chem. 1999. PMID: 10318772 Review. No abstract available.
• Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds.

  Turko IV, Ballard SA, Francis SH, Corbin JD. Turko IV, et al. Mol Pharmacol. 1999 Jul;56(1):124-30. doi: 10.1124/mol.56.1.124. Mol Pharmacol. 1999. PMID: 10385692
• Phosphodiesterase 5 inhibitors and nitrergic transmission-from zaprinast to sildenafil.

  Gibson A. Gibson A. Eur J Pharmacol. 2001 Jan 5;411(1-2):1-10. doi: 10.1016/s0014-2999(00)00824-4. Eur J Pharmacol. 2001. PMID: 11137852 Review.